1. Induction therapy and maintenance therapy for mantle-cell lymphoma with lenalidomide plus rituximab was found to be effective and safe. 2. ...
In this section, we highlight the key high-impact studies, updates, and analyses published in medicine during the past week. Use ...
1. Progression-free survival was improved by about 3 months with continuous lenalidomide-dexamethasone compared to standard melphalan-prednisone-thalidomide. 2. Overall survival was ...
1. The addition of lenalidomide to standard R-CHOP chemotherapy reduced the negative prognostic impact of non-GCB phenotype in diffuse large ...
Image: PD 1. Most treatment-naïve patients with chronic lymphocytic leukemia (CLL) safely tolerated escalating doses of combined lenalidomide and rituximab. 2. ...
In this section, we will highlight the key high-impact studies, updates, and analyses published in medicine during the past week. ...
Image: CC/Osaro 1. Treatment with lenalidomide and dexamethasone significantly delayed disease progression in patients with smoldering multiple myeloma who were ...
2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.
No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.
2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.
© 2021 2 Minute Medicine, Inc. - Physician-written medical news.
© 2021 2 Minute Medicine, Inc. - Physician-written medical news.